Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of XNW5004 plus enzalutamide in metastatic castration-resistant prostate cancer after failure of prior novel endocrine therapy
CTR20230362Phase 2Active
- Sponsor
- Sinovent
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of igermetostat, enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sinovent. Started Apr 2023; status: active.
02
Drugs
igermetostatenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20230362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230362.